Investigation of mast cell toll-like receptor 3 in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Systemic Mastocytosis using the novel application of autoMACS magnetic separation and flow cytometry. — CFSMEATLAS
Investigation of mast cell toll-like receptor 3 in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Systemic Mastocytosis using the novel application of autoMACS magnetic separation and flow cytometry.
Balinas, Cassandra, Nguyen, Thao, Johnston, Samantha et al. · Asian Pacific journal of allergy and immunology · 2018 · DOI
Quick Summary
This study looked at immune cells called mast cells in people with ME/CFS, comparing them to people with a known mast cell disorder and healthy volunteers. Mast cells help the body fight viruses and allergies. The researchers found differences in how these cells behave when exposed to viral-like substances, suggesting mast cells may play a role in ME/CFS symptoms.
Why It Matters
Many ME/CFS patients report viral infection triggers and allergic-type symptoms; understanding mast cell dysfunction could explain these experiences and guide treatment development. This study provides a novel, less invasive method to study immune dysfunction in ME/CFS, potentially enabling future large-scale investigations.
Observed Findings
Significant decrease in HLA-DR+/CD154- expression in ME/CFS participants compared to systemic mastocytosis participants both before and after viral stimulation.
Increase in HLA-DR-/CD154+ expression in ME/CFS participants following Poly I:C stimulation.
No significant differences in mast cell progenitor maturity markers between ME/CFS, systemic mastocytosis, and healthy control groups.
No significant differences in CD2/CD25 expression (systemic mastocytosis-specific markers) between groups.
Inferred Conclusions
Mast cell progenitors may be involved in ME/CFS pathophysiology, distinct from systemic mastocytosis.
Altered immune interaction receptor expression in ME/CFS mast cells suggests an atypical immune response to viral-like stimuli.
Further investigation is needed to determine the immunological role and clinical significance of these cellular changes.
Remaining Questions
What is the functional consequence of altered HLA-DR and CD154 expression on mast cell activation and cytokine release in ME/CFS?
Do these mast cell differences correlate with symptom severity or disease progression in ME/CFS patients?
How do these findings translate to mast cell behavior in tissues (not just peripheral blood) relevant to ME/CFS symptoms?
What This Study Does Not Prove
This pilot study does not prove that mast cell dysfunction causes ME/CFS symptoms, nor does it establish the clinical significance of the observed molecular differences. The small sample size and lack of longitudinal follow-up mean findings may not represent the broader ME/CFS population or predict disease progression.